620 related articles for article (PubMed ID: 28577742)
1. Dual renin-angiotensin system blockade for nephroprotection.
Ruggenenti P
Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
[TBL] [Abstract][Full Text] [Related]
2. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
Gentile G; Remuzzi G; Ruggenenti P
Nephron; 2015; 129(1):39-41. PubMed ID: 25531311
[TBL] [Abstract][Full Text] [Related]
3. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
4. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
5. Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
Soares AE; Maes M; Godeny P; Matsumoto AK; Barbosa DS; da Silva TAF; Souza FHMO; Delfino VDA
Life Sci; 2017 Dec; 191():175-179. PubMed ID: 29079468
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
[TBL] [Abstract][Full Text] [Related]
7. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
9. Transforming the Care of Patients with Diabetic Kidney Disease.
Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
MacKinnon M; Shurraw S; Akbari A; Knoll GA; Jaffey J; Clark HD
Am J Kidney Dis; 2006 Jul; 48(1):8-20. PubMed ID: 16797382
[TBL] [Abstract][Full Text] [Related]
13. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
14. Targeting the renin angiotensin system for remission/regression of chronic kidney disease.
Macconi D
Histol Histopathol; 2010 May; 25(5):655-68. PubMed ID: 20238303
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
Mavrakanas TA; Gariani K; Martin PY
Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
[TBL] [Abstract][Full Text] [Related]
17. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.
Berl T
J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):1-8. PubMed ID: 19286752
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
19. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
20. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
